Lu-PSMA-617 plus pembrolizumab shows PSA response in mCRPC phase 1b/2 trial
Can a new drug combo help men with advanced prostate cancer?
In a single-arm phase 1b/2 trial of 37 patients with mCRPC, Lu-PSMA-617 plus pembrolizumab achieved a 50% PSA decline in 28 participants (76…
A new drug combo helped 28 of 37 men with advanced prostate cancer cut their PSA levels in half while keeping side effects mostly mild to mo…
CDSS Dashboard Implementation Associated with Higher CRPC Detection in Prostate Cancer Cohort
Can a digital dashboard help doctors spot prostate cancer progression sooner?
A retrospective single-centre cohort study of prostate cancer patients on ADT found that implementing a Clinical Decision Support System das…
A digital dashboard helped doctors spot prostate cancer progression sooner and catch unstable warning signs in patients already on hormone t…
Phase II study of 177Lu-PSMA-617 in mCRPC shows 50% PSA response and median OS of 18.8 months
Can a targeted radiation treatment help men with advanced prostate cancer?
A prospective, single-arm phase II study of 48 PSMA-avid mCRPC patients treated with 177Lu-PSMA-617 found a 50% PSA response rate and median…
A targeted radiation therapy helped half of men with advanced prostate cancer lower their cancer markers and kept nearly 88% alive after one…
Meta-analysis finds 47% PSA decline >50% with Ac-225/Lu-177 PSMA combination in mCRPC
Can a new two-drug radiation combo help men with advanced prostate cancer?
A meta-analysis of 323 patients with mCRPC found that Ac-225/Lu-177 PSMA radioligand combination therapy was associated with a pooled PSA de…
A new two-drug radiation combo helped 78% of men with advanced prostate cancer lower their PSA levels, with nearly half seeing a substantial…
Research across Metastatic hormone-sensitive prostate cancer
Related studies from across the Metastatic hormone-sensitive prostate cancer family.
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Enzalutamide plus ADT improves 5-year survival in metastatic hormone-sensitive prostate cancer
Prostate Cancer Drug Helps Men Live Years Longer, New Data Shows
This post hoc analysis of a phase 3 randomized controlled trial in 1150 patients with metastatic hormone-sensitive prostate cancer found tha…
Men with advanced prostate cancer who took enzalutamide lived years longer than those on standard treatment alone, according to five-year da…
Darolutamide plus ADT delays pain progression in metastatic hormone-sensitive prostate cancer
New treatment delays pain in advanced prostate cancer
This randomised, double-blind, phase 3 trial in men with metastatic hormone-sensitive prostate cancer found that darolutamide plus androgen …
Men with advanced prostate cancer who took darolutamide stayed pain-free longer and felt better overall for months compared to those on stan…
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohort
What happens when prostate cancer spreads to bones at diagnosis?
A retrospective cohort study of patients with synchronous bone-metastatic hormone-sensitive prostate cancer at a Chinese tertiary center fou…
About 6% of men diagnosed with prostate cancer already have it spread to their bones, where high-volume disease doubles the risk of death.
Questions about Metastatic Castration Resistant Prostate Cancer
What barriers exist for using PSMA-directed CAR-T cell therapy to treat my cancer?
PSMA-directed CAR-T therapy for mCRPC faces barriers including a hostile tumor microenvironment, antigen heterogeneity, and T-cell limitations, but new platforms like iPSC-derived CAR-T are being explored.
Full answer →Does finding new lesions after lutetium-177 treatment mean my overall survival will be worse?
Yes, a meta-analysis found that new lesions after lutetium-177 treatment are linked to worse overall survival in mCRPC patients.
Full answer →